AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10740903 — intervention group
Group type: EXPERIMENTAL
Intervention: DHE diet and OHI, at home, once a year only
Number of subjects: 228
Study 10740903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DHE)
Number of subjects: 228
Study 8557129 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids in patients with ovulatory factor
Number of subjects: 169
Study 8557129 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids in patients with unexplained infertility
Number of subjects: 169
Study 1410164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (0.4, 0.6, and 0.8 mg subcutaneously)
Number of subjects: 70
Study 3935346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclo (His‐Pro), 400 micrograms intravenously
Number of subjects: 0
Study 30681054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 29016452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal tamponades (silicone oil and gas)
Number of subjects: 73
Study 29016452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intravitreal tamponades)
Number of subjects: 73
Study 29016452 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil tamponade
Number of subjects: 73
Study 29016452 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas tamponade
Number of subjects: 73
Study 25073857 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Sensitization (IS)
Number of subjects: 2056
Study 25073857 — intervention group
Group type: COMPARATOR
Intervention: Insulin Provision (IP)
Number of subjects: 2056
Study 24507437 — intervention group
Group type: EXPERIMENTAL
Intervention: FNAB performed by the radiologist alone (study group)
Number of subjects: 203
Study 24507437 — intervention group
Group type: COMPARATOR
Intervention: FNAB performed by the radiologist with a cytopathologist (control group)
Number of subjects: 203
Study 23195963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enteric insulin 50 U
Number of subjects: 12
Study 23195963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enteric insulin 100 U
Number of subjects: 12
Study 23195963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enteric insulin 200 U
Number of subjects: 12
Study 23195963 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin 6 U
Number of subjects: 12
Study 19241302 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg misoprostol
Number of subjects: 162
Study 19241302 — intervention group
Group type: COMPARATOR
Intervention: 200 microg misoprostol
Number of subjects: 162
Study 17541030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispatcher-assisted CPR with AED operation
Number of subjects: 54
Study 17541030 — intervention group
Group type: COMPARATOR
Intervention: Dispatcher-assisted CPR without AED operation
Number of subjects: 54
Study 15385809 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (two 20-mg doses on days 0 and 4) + Tacrolimus (0.15 mg/kg/day; target trough levels 10-15 ng/mL)
Number of subjects: 50
Study 15385809 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab + Tacrolimus
Number of subjects: 50
Study 11353902 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation (exposed-group)
Number of subjects: 30
Study 11353902 — intervention group
Group type: COMPARATOR
Intervention: Non-transplanted women (non-exposed group)
Number of subjects: 30
Study 11353902 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk of breast pathology occurrence
Number of subjects: 30
Study 9714353 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Steinbrocker's (MS) radiological scoring method
Number of subjects: 68
Study 9714353 — intervention group
Group type: EXPERIMENTAL
Intervention: Larsen's (L) radiological scoring method
Number of subjects: 68
Study 9714353 — intervention group
Group type: COMPARATOR
Intervention: Original Steinbrocker's (OS) radiological scoring method
Number of subjects: 68
Study 8790563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-S vaccine (12 micrograms, 24 micrograms, 48 micrograms)
Number of subjects: 87
Study 8790563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-S vaccine (48 micrograms)
Number of subjects: 87
Study 8790563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-S vaccine (any dose)
Number of subjects: 87
Study 8790563 — intervention group
Group type: COMPARATOR
Intervention: Recombivax-HB (10 micrograms)
Number of subjects: 87
Study 2924936 — intervention group
Group type: EXPERIMENTAL
Intervention: LH-timed intrauterine insemination
Number of subjects: 47
Study 2924936 — intervention group
Group type: COMPARATOR
Intervention: LH-timed natural intercourse
Number of subjects: 47
Study 29596853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg twice daily
Number of subjects: 80
Study 24827938 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week simulated developmental horse-riding program (SDHRP) combined with fitness training
Number of subjects: 48
Study 24827938 — intervention group
Group type: COMPARATOR
Intervention: Control group with ADHD (no intervention)
Number of subjects: 48
Study 24827938 — intervention group
Group type: COMPARATOR
Intervention: Typically developing (TD) control group (no intervention)
Number of subjects: 48
Study 26465164 — intervention group
Group type: EXPERIMENTAL
Intervention: Gsup (supervised)
Number of subjects: 87
Study 26465164 — intervention group
Group type: EXPERIMENTAL
Intervention: Gobs (not supervised)
Number of subjects: 87
Study 26465164 — intervention group
Group type: COMPARATOR
Intervention: Gref (no exercise program)
Number of subjects: 87
Study 24267730 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) 10 mg/d plus Exemestane (EXE) 25 mg/d
Number of subjects: 724
Study 24267730 — intervention group
Group type: COMPARATOR
Intervention: Exemestane (EXE) 25 mg/d
Number of subjects: 724
Study 24267730 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) plus Exemestane (EXE)
Number of subjects: 724
Study 21603651 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAX 0.2 mg via electroporation
Number of subjects: 35
Study 21603651 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAX 1 mg via electroporation
Number of subjects: 35
Study 21603651 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAX 4 mg via electroporation
Number of subjects: 35
Study 21603651 — intervention group
Group type: COMPARATOR
Intervention: ADVAX 4 mg via standard intramuscular injection
Number of subjects: 35
Study 21603651 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo via electroporation
Number of subjects: 35
Study 21603651 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAX 4 mg via electroporation (third vaccination at week 36)
Number of subjects: 35
Study 17473542 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa)
Number of subjects: 0
Study 17473542 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15064942 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. iron dextran
Number of subjects: 35
Study 15064942 — intervention group
Group type: COMPARATOR
Intervention: oral iron
Number of subjects: 35
Study 11996476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 20 mg/m2 (or 15 mg/m2 if prior pelvic radiotherapy) combined with estramustine phosphate (EMP) at 280 mg orally tds for 3 days, then every other week after 8 weeks
Number of subjects: 23
Study 11996476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine and EMP regimen
Number of subjects: 23
Study 9659028 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.02 mg.kg‐1
Number of subjects: 40
Study 9659028 — intervention group
Group type: COMPARATOR
Intervention: normal saline (control)
Number of subjects: 40
Study 8085286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 233
Study 8085286 — intervention group
Group type: COMPARATOR
Intervention: High-performance liquid chromatography (HPLC)
Number of subjects: 233
Study 8085286 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody assays (MAAs)
Number of subjects: 233
Study 8085286 — intervention group
Group type: EXPERIMENTAL
Intervention: MAA values of 10, 15, and 20 micrograms/ml
Number of subjects: 233
Study 2685221 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 20
Study 2685221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 788774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 75
Study 788774 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol
Number of subjects: 75
Study 788774 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 75
Study 788774 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone propionate
Number of subjects: 75
Study 788774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 29883983 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Reproductive Technology (ART)
Number of subjects: 381
Study 29883983 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous conception
Number of subjects: 381
Study 25451608 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccine
Number of subjects: 25
Study 25451608 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 25
Study 23057495 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (oxaliplatin 50 mg/m² on days 1, 8, 22, and 29; S-1 80 mg/m² per day on days 1-14 and 22-35)
Number of subjects: 38
Study 23057495 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (preoperative chemoradiation)
Number of subjects: 38
Study 21235683 — intervention group
Group type: EXPERIMENTAL
Intervention: folinic acid/fluorouracil/irinotecan
Number of subjects: 41
Study 21235683 — intervention group
Group type: EXPERIMENTAL
Intervention: folinic acid/fluorouracil/irinotecan + recombinant human endostatin
Number of subjects: 41
Study 18294023 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 18294023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16503693 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training group (STG)
Number of subjects: 180
Study 16503693 — intervention group
Group type: EXPERIMENTAL
Intervention: Local muscle endurance training group (ETG)
Number of subjects: 180
Study 16503693 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 180
Study 15160576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyalofill-F plus compression bandaging
Number of subjects: 0
Study 15160576 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent gauze plus compression therapy
Number of subjects: 0
Study 11176329 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS) with smectite
Number of subjects: 804
Study 11176329 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) alone
Number of subjects: 804
Study 9847464 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron beam treatment (9/12 MeV and 12 MeV) to chest wall and drainage area, 50 Gy over 5 weeks at 2 Gy per fraction.
Number of subjects: 50
Study 9847464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) for pre-menopausal patients with axillary node involvement.
Number of subjects: 50
Study 9847464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen 10 mg bid for post-menopausal patients.
Number of subjects: 50
Study 9847464 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (Electron beam)
Number of subjects: 50
Study 8008800 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week cognitive-behavioral course
Number of subjects: 150
Study 8008800 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 150
Study 2643331 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide tablets (500 mg)
Number of subjects: 0
Study 2643331 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide Sequels
Number of subjects: 0
Study 2643331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide tablets
Number of subjects: 0
Study 2643331 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous treatment with carbonic anhydrase inhibitors
Number of subjects: 0
Study 788494 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplemented formula (4 mg/liter of zinc)
Number of subjects: 0
Study 788494 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplemented formula
Number of subjects: 0
Study 30676819 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic preconditioning (pure oxygen for 5 min prior to balance test)
Number of subjects: 19
Study 30676819 — intervention group
Group type: COMPARATOR
Intervention: Nonhyperoxic preconditioning (chamber air for 5 min prior to balance test)
Number of subjects: 19
Study 30676819 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic preconditioning
Number of subjects: 19
Study 27883201 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA-2291 (25 mg, 50 mg, 100 mg)
Number of subjects: 54
Study 27883201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26361971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus bevacizumab
Number of subjects: 837
Study 26361971 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab alone
Number of subjects: 837
Study 26361971 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 837
Study 23913103 — intervention group
Group type: EXPERIMENTAL
Intervention: Salud y Bienestar program (diabetes education delivered by community health promoters)
Number of subjects: 1413
Study 20577750 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppositories containing genistein (97 μg daily for 15 days/month for 3 months)
Number of subjects: 62
Study 20577750 — intervention group
Group type: COMPARATOR
Intervention: Vaginal suppositories containing hyaluronic acid (5 mg daily for 15 days/month for 3 months)
Number of subjects: 62
Study 19344224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous EPO (30,000 U) every 48 hours for a total of 90,000 U
Number of subjects: 80
Study 16765169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally 1 hour before UDS
Number of subjects: 192
Study 16765169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 192
Study 16281654 — intervention group
Group type: EXPERIMENTAL
Intervention: alendronate/calcium (10 mg/600 mg day)
Number of subjects: 145
Study 16281654 — intervention group
Group type: COMPARATOR
Intervention: placebo/calcium
Number of subjects: 145
Study 11353880 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Expert system
Number of subjects: 557
Study 11353880 — intervention group
Group type: COMPARATOR
Intervention: Traditional management (seven nutritional visits over the year)
Number of subjects: 557
Study 11353880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Nutri-Expert and traditional management)
Number of subjects: 557
Study 9204353 — intervention group
Group type: EXPERIMENTAL
Intervention: iopentol
Number of subjects: 73
Study 9204353 — intervention group
Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 73
Study 8109217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (serum ethanol concentration of 0.98 +/- 0.22 g/l)
Number of subjects: 13
Study 3311904 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1 g dose tetracycline
Number of subjects: 118
Study 3311904 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2 g dose tetracycline
Number of subjects: 118
Study 3311904 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose tetracycline (500 mg every six hours, four times)
Number of subjects: 118
Study 3311904 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 118
Study 31906054 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped learning
Number of subjects: 119
Study 31906054 — intervention group
Group type: COMPARATOR
Intervention: Traditional methodology
Number of subjects: 119
Study 29613816 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLR knee
Number of subjects: 43
Study 26732944 — intervention group
Group type: EXPERIMENTAL
Intervention: CINV control (total control: no vomiting, no nausea, and no rescue medication)
Number of subjects: 177
Study 26732944 — intervention group
Group type: EXPERIMENTAL
Intervention: CINV control (no vomiting)
Number of subjects: 177
Study 26732944 — intervention group
Group type: EXPERIMENTAL
Intervention: CINV control rates in acute and delayed periods
Number of subjects: 177
Study 26732944 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of nausea measures in primary study outcome
Number of subjects: 177
Study 24622816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) performed three times daily for 5 days at a dosage of 1.4 J/cm(2)
Number of subjects: 54
Study 24622816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 54
Study 22297422 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucella abortus strain RB51 vaccine (recommended vaccine dose twice 4 weeks apart)
Number of subjects: 32
Study 22297422 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucella abortus strain RB51 vaccine (recommended vaccine dose twice 18 weeks apart)
Number of subjects: 32
Study 22297422 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, once)
Number of subjects: 32
Study 22297422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both selective media used for isolation of RB51
Number of subjects: 32
Study 19562997 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic autotransplantation combined with lower esophagus transaction anastomosis
Number of subjects: 36
Study 19562997 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy combined with lower esophagus transaction anastomosis
Number of subjects: 36
Study 17451339 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic nephrectomy (RN) for giant hydronephrosis (GH); mean operating time 126 minutes (range 65-240 minutes), estimated blood loss 101 mL (range 5-450 mL), mean length of hospital stay 2.9 days (range 1.5-6 days).
Number of subjects: 11
Study 17451339 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneoscopic nephrectomy (RN) for small nonfunctioning kidneys (SNFK); mean operating time 116 minutes (range 55-270 minutes), estimated blood loss 46 mL (range 5-400 mL), mean length of stay 2.8 days (range 1-5 days).
Number of subjects: 11
Study 15694571 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate care with hylan G-F 20 (AC+H)
Number of subjects: 255
Study 15694571 — intervention group
Group type: COMPARATOR
Intervention: Appropriate care without hylan G-F 20 (AC)
Number of subjects: 255
Study 11948386 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning during phototherapy
Number of subjects: 30
Study 11948386 — intervention group
Group type: COMPARATOR
Intervention: Supine position during phototherapy
Number of subjects: 30
Study 9829838 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage-colony-stimulating factor (GM-CSF)
Number of subjects: 18
Study 9829838 — intervention group
Group type: COMPARATOR
Intervention: Non-GM-CSF
Number of subjects: 18
Study 7667561 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian interpretation of the penalized likelihood
Number of subjects: 0
Study 7667561 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptotic distribution of the maximum penalized likelihood estimates
Number of subjects: 0
Study 2763811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia at 12,500 ft (3810 m)
Number of subjects: 40
Study 2763811 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia at 15,000 ft (4572 m)
Number of subjects: 40
Study 2763811 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response from sea level to all four altitudes
Number of subjects: 40
Study 779465 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, oral, streptomycin-dependent Shigella sonnei vaccine
Number of subjects: 0
Study 779465 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31088893 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting Early Program (early child obesity prevention intervention)
Number of subjects: 100
Study 28170098 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 57
Study 25600248 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 25600248 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0
Study 25600248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24405838 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25mg/day)
Number of subjects: 16
Study 24405838 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (20mg/day)
Number of subjects: 16
Study 22950667 — intervention group
Group type: EXPERIMENTAL
Intervention: Iota-carrageenan nasal spray (0.12%)
Number of subjects: 153
Study 22950667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 153
Study 19574171 — intervention group
Group type: EXPERIMENTAL
Intervention: Maylard incision
Number of subjects: 80
Study 19574171 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel incision
Number of subjects: 80
Study 17414581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine microgranules (NMG) 30 mg/day
Number of subjects: 192
Study 17414581 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine osmotic pump (NOP) 30 mg/day
Number of subjects: 192
Study 15191321 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized Dynamic Fuzzy Neural Networks (GDFNN)
Number of subjects: 343
Study 15992694 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative regional chemotherapy with fluorouracil followed by systemic chemotherapy with fluorouracil and folinic acid (n=368) or with fluorouracil and levamisole (n=380).
Number of subjects: 1501
Study 15992694 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy alone (379 with fluorouracil and folinic acid, and 374 with fluorouracil and levamisole).
Number of subjects: 1501